Borean Pharma receives Notice of Allowance of HIV drug patent by U.S. Patent & Trademark Office
Borean's HIV drug candidates are trimeric fusion proteins. These represent a next generation in HIV fusion inhibitors that are expected to combine greater patient safety and convenience with lower production and treatment costs.
"HIV remains one of the greatest challenges for medicine and this patent is therefore tremendously important to us," stated Dr. Johanna Holldack, CEO of Borean Pharma. "The acceptance of this patent is a significant milestone for Borean Pharma because it continues to solidify the positioning of our technologies and products."
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.